Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

The FDA has approved a supplemental New Drug Application (sNDA) for apalutamide (Erleada) for the treatment of patients with metastatic... Read More

Choosing Between Docetaxel or Abiraterone With ADT in Hormone-Sensitive Prostate Cancer

Findings from the CHAARTED, LATITUDE, and STAMPEDE trials1-3 showed various results for adding docetaxel (Taxotere) or abiraterone acetate (Zytiga) to androgen... Read More

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

An analysis of the genomic landscape of patients with prostate cancer shows that tumors separated into 3 clusters that aligned... Read More

Addressing the Important Role of Genetic Testing in Prostate Cancer

As researchers learn more about prostate cancer and the important role that genetic testing can play for patients and their... Read More

Researchers Shed Light on Previously Unidentified Commonly Mutated Genes in Prostate Cancer

In an effort to shed light on the genetic differences between primary and metastatic prostate cancer, researchers recently analyzed a... Read More

Docetaxel Continues to Show Profound Benefits in Prostate Cancer

Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer,... Read More

Circulating Tumor Cells as Possible Clinical Endpoint in Prostate Cancer Trials

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. Mark Stein, MD, says that... Read More